*NEW* RESEARCH UPDATE FROM BIOHAVEN RE: VERDIPERSTAT (BHV-3241)

Timeline: International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy

“Top line results from the study are expected to be available in 3rd Quarter of 2021 and will help to characterize the potential benefits and risks of Verdiperstat in MSA. After the study results are available, Biohaven will provide further updates on the development of Verdiperstat for the treatment of MSA.”

For information on the Mechanism of Action (MOA), please click below to access a video explaining Verdiperstat:

CLICK TO DOWNLOAD UPDATE FROM BIOHAVEN MAY 2021

AND

CLICK BELOW TO VIEW VIDEO ON VERDIPERSTAT:

0 Comments

Other posts you might like

Comunicacion de Biohaven Pharmaceuticals en Idioma Espanol

Preguntas proactivas: se pueden publicar en línea ¿Puedo seguir uniéndome al ensayo?                                                                                        La inscripción para el estudio en fase III cerró en julio de 2020. ¿Cuándo se espera que...

read more
MSA AWARENESS MONTH ACTIVITIES

MSA AWARENESS MONTH ACTIVITIES

 A Few of Activities For MSA Awareness Month... 1) EAT CAKE. GIVE HOPE. DEFEAT MSA. Join Annual Cake 4 A Cure Campaign! Read About an Amazing and Successful Campaign: Cake4aCure.org   Also, the Facebook page for more details: https://www.facebook.com/Cake4aCure 2)...

read more

Subscribe For Research Updates & Resources

* indicates required





Postal Mail

MSA United International
29924 Jefferson Avenue
Saint Clair Shores, Michigan  48082
USA

Contact Us

Are you a researcher ? Click here to submit your contact information